Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab

被引：0

作者：

Massimo Gentile

Tait D. Shanafelt

Gianluigi Reda

Francesca Romana Mauro

Katja Zirlik

Stefania Ciolli

Luca Laurenti

Maria Ilaria Del Principe

Davide Rossi

Nicola Di Renzo

Stefano Molica

Francesco Angrilli

Marta Coscia

Annalisa Chiarenza

Annamaria Giordano

Giovanna Cutrona

Kari G. Chaffee

Sameer A. Parikh

Giuseppina Uccello

Idanna Innocenti

Giovanni Tripepi

Graziella D’Arrigo

Ernesto Vigna

Anna Grazia Recchia

Yair Herishanu

Lev Shvidel

Tamar Tadmor

Agostino Cortelezzi

Giovanni Del Poeta

Gianluca Gaidano

Francesco Di Raimondo

Antonino Neri

Manlio Ferrarini

Robin Foà

Aaron Polliack

Fortunato Morabito

机构：

[1] A.O. of Cosenza,Hematology Unit, Department of Onco

[2] Stanford University,Hematology

[3] Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico and University of Milan,Department of Medicine, Division of Hematology

[4] ‘Sapienza’ University,Hematology Unit

[5] University Medical Centre Freiburg,Hematology, Department of Cellular Biotechnologies and Hematology

[6] University of Florence,Department of Haematology and Oncology

[7] Catholic University Hospital “A. Gemelli”,Department of Hematology

[8] Università degli studi di Roma “Tor Vergata”,Ematologia, Dipartimento di Biomedicina e Prevenzione

[9] Oncology Institute of Southern Switzerland and Institute of Oncology Research,Unità di Ematologia

[10] Ospedale Vito Fazzi,Department of Oncology and Haematology

[11] Pugliese-Ciaccio Hospital,Department of Hematology

[12] Ospedale Santo Spirito,Division of Haematology, University of Torino

[13] A.O. Città della Salute e della Scienza di Torino,Department of Biomedical Sciences, Division of Haematology

[14] University of Catania and Ferrarotto Hospital,Ematologia

[15] Policlinico Consorziale di Bari,Azienda Ospedaliero

[16] Ospedale Policlinico San Martino IRCCS,Universitaria

[17] Mayo Clinic,UO Molecular Pathology

[18] Mayo Clinic,Division of Biomedical Statistics and Informatics

[19] Instituto di Biomedicina ed Immunologia Molecolare,Department of Internal Medicine, Division of Hematology

[20] Azienda Sanitaria Provinciale di Cosenza,Consiglio Nazionale delle Ricerche

[21] Tel Aviv Sourasky Medical Center,Biotechnology Research Unit

[22] Kaplan Medical Center,Department of Hematology

[23] Bnai-Zion Medical Center,Hematology Institute

[24] Università del Piemonte Orientale,Hematology Unit

[25] Direzione Scientifica Ospedale Policlinico San Martino IRCCS,Division of Haematology, Department of Translational Medicine

[26] Hospital and Hebrew University Medical School,Department of Hematology, Hadassah University

来源：

Leukemia | 2018年 / 32卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1869 / 1873

页数：4

共 50 条

[21] What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?
Voorhies, Benjamin N.
Stephens, Deborah M.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (02)
[22] ECONOMIC EVALUATION OF BENDAMUSTINE PLUS RITUXIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Lachaine, J.
Kouroukis, C. T.
VALUE IN HEALTH, 2016, 19 (03) : A248 - A248
[23] Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Cramer, Paula
Chanan-Khan, Asher
Fraser, Graeme
Demirkan, Fatih
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Goy, Andre
Mayer, Jiri
Dilhuydy, Marie Sarah
Loscertales, Javier
Bartlett, Nancy L.
Avigdor, Abraham
Rule, Simon
Sun, Steven
Phelps, Charles
Mahler, Michelle
Salman, Mariya
Schaffer, Michael
Balasubramanian, Sriram
Howes, Angela
Hallek, Michael
BLOOD, 2015, 126 (23)
[24] Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients
O'Reilly, Alma
Murphy, James
Rawe, Sarah
Garvey, Mary
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (04): : 249 - 256
[25] EFFICACY OF THE COMBINATION OF BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Zagoskina, T.
Zotina, E.
Ovsepyan, V.
Shardakov, V.
HAEMATOLOGICA, 2014, 99 : 591 - 591
[26] Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia
Flinn, Ian W.
Cherry, Mohamad
Maris, Michael
Matous, Jeffrey V.
Berdeja, Jesus G.
Patel, Manish R.
BLOOD, 2015, 126 (23)
[27] Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia
Robak, T
Blonski, JZ
Kasznicki, M
Góra-Tybor, J
Dwilewicz-Trojaczek, J
Boguradzki, P
Konopka, L
Ceglarek, B
Sulek, J
Kuliczkowski, K
Wolowiec, D
Stella-Holowiecka, B
Skotnicki, AB
Nowak, W
Moskwa-Sroka, B
Dmoszynska, A
Calbecka, M
LEUKEMIA, 2001, 15 (10) : 1510 - 1516
[28] Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab–bendamustine
Ricardo García-Muñoz
Diana K. García
Verónica Roldán-Galiacho
Miriam Merchante-Andreu
Andrea Campeny-Najara
Pilar Rabasa
Annals of Hematology, 2014, 93 : 699 - 702
[29] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
Grifi, Fatiha
Bougherira, Soraya
Djenouni, Amel
LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94
[30] Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia
T Robak
JZ Błoński
M Kasznicki
J Góra-Tybor
J Dwilewicz-Trojaczek
P Boguradzki
L Konopka
B Ceglarek
J Sułek
K Kuliczkowski
D Wołowiec
B Stella-Hołowiecka
AB Skotnicki
W Nowak
B Moskwa-Sroka
A Dmoszyńska
M Calbecka
Leukemia, 2001, 15 : 1510 - 1516

← 1 2 3 4 5 →